New combo therapy aims to outperform standard care for advanced liver cancer

NCT ID NCT07594340

Recruiting now Disease control Sponsor: Binkui Li Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 3 trial tests whether a chemotherapy infusion directly into the liver (HAIC) plus immunotherapy drugs works better than the standard chemo-embolization procedure (TACE) plus the same immunotherapy for people with intermediate-stage liver cancer that has spread extensively. About 300 participants will be randomly assigned to one of the two treatment groups. The study aims to find a more effective way to control the cancer and improve survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: sintilimab and bevacizumab (immunotherapy drugs) plus either hepatic arterial infusion chemotherapy (HAIC) or transarterial chemoembolization (TACE)
What this could lead to: If this trial succeeds, it could show that HAIC combined with immunotherapy is more effective than the standard TACE approach for controlling liver cancer and extending survival in patients with a high tumor burden.
What could go wrong: This is a Phase 3 trial, but results are not yet available. The experimental treatment may not prove superior to the standard approach, and both combinations carry risks such as liver damage, bleeding, or immune-related side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA INTERMEDIATE-STAGE HEPATOCELLULAR CARCINOMA

Contacts and locations

Locations

Sun Yat-sen University Cancer Center
RECRUITING

Guangzhou, Guangdong, 510000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.